Medical Devices

TellDx-Enabled Circulating Tumor Cell Analysis Predicts Response to DLL3-Targeted Therapy in Small Cell Lung Cancer

01/20/2026

— Study Results Support the use of TellDx to Personalize Cancer Care Management – — Clinical study published in Cancer Discovery — Excerpt from the Press Release: ANDOVER, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) — TellBio, Inc., a medical technology company focused on revolutionizing the management of cancer through its unique and proprietary circulating tumor…

Frontier Medicines Announces Third Precision Oncology Development Candidate

10/22/2025

Excerpt from the Press Release: BOSTON and SOUTH SAN FRANCISCO, Calif. (October 14, 2025) – Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule, precision oncology and immunology drugs against previously undruggable disease-causing targets, today announced its latest development candidate. FMC-242 is a covalent allosteric inhibitor that breaks the interaction…

ADONA MEDICAL INITIATES FIRST-IN-HUMAN STUDY WITH ITS NOVEL INTERATRIAL SHUNT FOR PATIENTS WITH HEART FAILURE

10/30/2024

Excerpt from the Press Release: LOS GATOS, Calif., Oct. 27, 2024 /PRNewswire/ — Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced today the successful first-in-human use of its novel interatrial shunt in patients with heart failure. The initial cases were performed by George Khabeishvili, MD, at Tbilisi Heart…

Jupiter Endovascular Announces First Patients Successfully Treated in First Clinical Study of Vertex Pulmonary Embolectomy System Using Endoportal Control

09/26/2024

Vertex System Designed to Bring the Precision and Control of Direct Surgical Access to Catheter-Based Interventions Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control™, announced today that the first two patients have been treated in SPIRARE I (NCT06571760),…

Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control

09/05/2024

Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control™ to bring the precision and control of direct surgical access to catheter-based interventions, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption application…

First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG

03/25/2024

VALID-ECG Study will Form the Basis of the Company’s Upcoming FDA 510(k) Submission Excerpt from the Press Release: SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has enrolled the first patients in the VALID-ECG (Clinical Validation of…

SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration

03/21/2024

New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research Excerpt from the Press Release: BOSTON and ROLLE, Switzerland, March 15, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal…

1nhaler Raises £2 Million to Develop Single-Use Sustainable Inhaler

12/01/2023

Excerpt from the Press Release: Inhalable medicines are already widely used to treat conditions such as asthma, epilepsy, allergies and Parkinson’s but, to date, delivery options have been limited due to user accessibility, cost, performance and impact on the environment. 1nhaler has developed a way of enabling many different dry powder drugs to be readily…

Recor Medical Announces Positive Results from Six-Month Pooled Analysis of Data from the RADIANCE Global Clinical Trial Program at TCT 2023

11/06/2023

Analysis shows a maintained blood pressure lowering effect with fewer added medications following treatment with the Paradise Ultrasound Renal Denervation system Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced positive results from a combined analysis of six-month…

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

05/31/2023

-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to anti-PD(L)1 monotherapy Excerpt from the Press Release: RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients…